{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-053765","form_type":"8-K/A","ticker":"ELDN","cik":"0001404281","company_name":"Eledon Pharmaceuticals, Inc.","filed_at":"2025-04-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.179554+00:00","generated_at":"2026-05-23T15:22:27.918296+00:00","sec_items":["4.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Eledon Pharmaceuticals amends 8-K to correct auditor dismissal period; Crowe served only FY 2024","bullets":["Corrects prior 8-K that inadvertently referenced Crowe LLP for fiscal year 2023.","Audit Committee dismissed Crowe LLP and engaged Deloitte & Touche LLP on April 1, 2025.","Crowe served as auditor from July 10, 2024 to April 1, 2025; no disagreements or reportable events.","Deloitte engaged as independent auditor for fiscal year ending December 31, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-053765","json":"https://secwatch.observer/filing/0000950170-25-053765.json","markdown":"https://secwatch.observer/filing/0000950170-25-053765.md","text":"https://secwatch.observer/filing/0000950170-25-053765.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1404281/000095017025053765/0000950170-25-053765-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1404281/000095017025053765/eldn-20250401.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T15:22:27.918296+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}